Cited 7 times in
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍민희 | - |
dc.date.accessioned | 2024-03-22T06:14:56Z | - |
dc.date.available | 2024-03-22T06:14:56Z | - |
dc.date.issued | 2024-01 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198475 | - |
dc.description.abstract | Purpose: The phase III SKYSCRAPER-02 study determined whether the benefits of atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of tiragolumab in untreated extensive-stage small-cell lung cancer (ES-SCLC). We report final progression-free survival (PFS) and overall survival (OS) analyses. Methods: Patients received tiragolumab 600 mg/placebo, plus atezolizumab 1,200 mg and CE (four cycles), then maintenance tiragolumab/placebo plus atezolizumab. Primary end points were investigator-assessed PFS and OS in patients without history/presence of brain metastases (primary analysis set [PAS]). Additional end points included PFS and OS in all patients regardless of brain metastases status (full analysis set [FAS]), response, and safety. Results: Four hundred ninety patients were randomly assigned (FAS): 243 to tiragolumab arm and 247 to control arm. At the cutoff date (February 6, 2022; median duration of follow-up, 14.3 months [PAS] and 13.9 months [FAS]), final analysis of PFS in the PAS (n = 397) did not reach statistical significance (stratified hazard ratio [HR], 1.11; P = .3504; median, 5.4 months tiragolumab v 5.6 months control). At the cutoff date (September 6, 2022; median duration of follow-up, 21.2 months [FAS]), median OS in the PAS at final OS analysis was 13.1 months in both arms (stratified HR, 1.14; P = .2859). Median PFS and OS in the FAS were consistent with the PAS. The proportion of patients with immune-mediated adverse events (AEs) in the tiragolumab and control arms was 54.4% and 49.2%, respectively (grade 3/4: 7.9% and 7.7%). AEs leading to treatment withdrawal occurred in 8.4% and 9.3% of tiragolumab- and control-treated patients, respectively. Conclusion: Tiragolumab did not provide additional benefit over atezolizumab and CE in untreated ES-SCLC. The combination was well tolerated with no new safety signals. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Monoclonal / therapeutic use | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols* / adverse effects | - |
dc.subject.MESH | Brain Neoplasms / drug therapy | - |
dc.subject.MESH | Etoposide | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms* / drug therapy | - |
dc.subject.MESH | Lung Neoplasms* / pathology | - |
dc.subject.MESH | Small Cell Lung Carcinoma* / drug therapy | - |
dc.title | SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Charles M Rudin | - |
dc.contributor.googleauthor | Stephen V Liu | - |
dc.contributor.googleauthor | Ross A Soo | - |
dc.contributor.googleauthor | Shun Lu | - |
dc.contributor.googleauthor | Min Hee Hong | - |
dc.contributor.googleauthor | Jong-Seok Lee | - |
dc.contributor.googleauthor | Maciej Bryl | - |
dc.contributor.googleauthor | Daphne W Dumoulin | - |
dc.contributor.googleauthor | Achim Rittmeyer | - |
dc.contributor.googleauthor | Chao-Hua Chiu | - |
dc.contributor.googleauthor | Ozgur Ozyilkan | - |
dc.contributor.googleauthor | Melissa Johnson | - |
dc.contributor.googleauthor | Alejandro Navarro | - |
dc.contributor.googleauthor | Silvia Novello | - |
dc.contributor.googleauthor | Yuichi Ozawa | - |
dc.contributor.googleauthor | Sammi Hiu Tam | - |
dc.contributor.googleauthor | Namrata S Patil | - |
dc.contributor.googleauthor | Xiaohui Wen | - |
dc.contributor.googleauthor | Meilin Huang | - |
dc.contributor.googleauthor | Tien Hoang | - |
dc.contributor.googleauthor | Raymond Meng | - |
dc.contributor.googleauthor | Martin Reck | - |
dc.identifier.doi | 10.1200/jco.23.01363 | - |
dc.contributor.localId | A04393 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.pmid | 37976444 | - |
dc.contributor.alternativeName | Hong, Min Hee | - |
dc.contributor.affiliatedAuthor | 홍민희 | - |
dc.citation.volume | 42 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 324 | - |
dc.citation.endPage | 335 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.42(3) : 324-335, 2024-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.